Can genetic variations predict HCV treatment outcomes?

Journal of Hepatology

Volumn 49, Issue 4, 2008, Pages 494-497

  Selzner, Nazia ^a   McGilvray, Ian ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gene polymorphism; HCV; SNP

Indexed keywords

CXCL9 CHEMOKINE; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEGINTERFERON ALPHA; RIBAVIRIN;

EDITORIAL; GENE CONTROL; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 50549099455     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.006     Document Type: Editorial

References (29)

1. Selzner N., Chen L., Borozan I., Edwards A., Heathcote E.J., and McGilvray I. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J Hepatol 48 (2008) 708-713
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
4. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
5. Morgan T.R., Lambrecht R.W., Bonkovsky H.L., Chung R.T., Naishadham D., Sterling R.K., et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. J Hepatol 49 (2008) 548-556
6. Chen L., Borozan I., Feld J., Sun J., Tannis L.L., Coltescu C., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 1437-1444
7. Feld J.J., Nanda S., Huang Y., Chen W., Cam M., Pusek S.N., et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46 (2007) 1548-1563
8. Asselah T., Bieche I., Narguet S., Sabbagh A., Laurendeau I., Ripault M.P., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57 (2008) 516-524
9. Chen L., Borozan I., Sun J., Anand N., Heathcote E.J., Edwards A., et al. Validation of a gene signature predicting response to treatment in chronic hepatitis C virus infection. Hepatology A46 (2007) 256
10. Lempicki R.A., Polis M.A., Yang J., McLaughlin M., Koratich C., Huang D.W., et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193 (2006) 1172-1177
11. Taylor M.W., Tsukahara T., Brodsky L., Schaley J., Sanda C., Stephens M.J., et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81 (2007) 3391-3401
12. Houldsworth A., Metzner M., Rossol S., Shaw S., Kaminski E., Demaine A.G., et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 25 (2005) 271-276
13. Suzuki F., Arase Y., Suzuki Y., Tsubota A., Akuta N., Hosaka T., et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 11 (2004) 271-276
14. Abbas Z., Moatter T., Hussainy A., and Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 11 (2005) 6656-6661
15. Hijikata M., Ohta Y., and Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 43 (2000) 124-127
16. Knapp S., Yee L.J., Frodsham A.J., Hennig B.J., Hellier S., Zhang L., et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 4 (2003) 411-419
17. Naito M., Matsui A., Inao M., Nagoshi S., Nagano M., Ito N., et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40 (2005) 381-388
18. Gao B., Hong F., and Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39 (2004) 880-890
19. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 (2002) 694-703
20. + T cell responses in an acutely infected chimpanzee. Hepatology 38 (2003) 1297-1306
21. Huang Y., Yang H., Borg B.B., Su X., Rhodes S.L., Yang K., et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 104 (2007) 985-990
22. Tsuruma T., Yagihashi A., Torigoe T., Sato N., Kikuchi K., Watanabe N., et al. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells. Cell Immunol 184 (1998) 121-128
23. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 (1991) 1209-1220
24. Eskdale J., Gallagher G., Verweij C.L., Keijsers V., Westendorp R.G., and Huizinga T.W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 95 (1998) 9465-9470
25. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., and Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30 (1999) 526-530
26. Eskdale J., Keijsers V., Huizinga T., and Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1 (1999) 151-155
27. Yee L.J., Tang J., Gibson A.W., Kimberly R., Van Leeuwen D.J., and Kaslow R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33 (2001) 708-712
28. Shastry B.S. SNPs in disease gene mapping, medicinal drug development and evolution. J Hum Genet 52 (2007) 871-880
29. Roden D.M., Altman R.B., Benowitz N.L., Flockhart D.A., Giacomini K.M., Johnson J.A., et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 145 (2006) 749-757